Transdermal lontophoretic delivery of triptorelin in vitro

被引:29
作者
Schuetz, YB
Naik, A
Guy, RH
Vuaridel, E
Kalia, YN [1 ]
机构
[1] Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva, Switzerland
[2] Ctr Interuniv Rech & Enseignement Pharmapeptides, F-74160 Archamps, France
[3] Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva, Switzerland
[4] Debiopharm Galen Unit, CH-1196 Gland, Switzerland
关键词
transdermal iontophoresis; triptorelin; electroosmosis; electroosmosis inhibition;
D O I
10.1002/jps.20433
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
The feasibility of delivering triptorelin ([D-Trp(6)]LHRH) by transdermal iontophoresis was evaluated in vitro. Peptide electrotransport at different current densities and donor concentrations was measured across porcine ear skin. The concomitant delivery of an electroosmotic marker enabled calculation of the respective contributions of electromigration (EM) and electroosmosis (EO) to iontophoretic delivery. At a given concentration (3 mM), a threefold increase in current density produced a corresponding increase in the cumulative amount of peptide present in the receptor compartment. Conversely, doubling the concentration to 6 mM produced a twofold reduction in the amount of peptide delivered, partly due to a concentration-dependent inhibition of EO. EM was revealed to be the predominant transport mechanism, accounting for 80% of overall delivery. Finally, despite the inhibition of EO, the results indicate that application of an iontophoretic current of 0.8 mA over a relatively small contact area (4 cm(2)) would provide a delivery rate of 36 mu g/h, largely sufficient for therapeutic requirements. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:2175 / 2182
页数:8
相关论文
共 29 条
[1]
[Anonymous], SKIN BARRIER PRINCIP
[2]
Iontophoresis of nafarelin across human skin in vitro [J].
Bayon, AMR ;
Guy, RH .
PHARMACEUTICAL RESEARCH, 1996, 13 (05) :798-800
[3]
Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: Results of an open pharmacodynamic and pharmacokinetic multicenter study [J].
Bouchot, O ;
Soret, JY ;
Jacqmin, D ;
Lahlou, N ;
Roger, M ;
Blumberg, J .
HORMONE RESEARCH, 1998, 50 (02) :89-93
[4]
Bronaugh R.L., 1991, IN VITRO PERCUTANEOU, P1
[5]
COMPARISON BETWEEN THE IONTOPHORETIC AND PASSIVE TRANSPORT OF THYROTROPIN-RELEASING-HORMONE ACROSS EXCISED NUDE-MOUSE SKIN [J].
BURNETTE, RR ;
MARRERO, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (08) :738-743
[6]
IONTOPHORESIS OF A MODEL PEPTIDE ACROSS HUMAN SKIN IN-VITRO - EFFECTS OF IONTOPHORESIS PROTOCOL, PH, AND IONIC-STRENGTH ON PEPTIDE FLUX AND SKIN IMPEDANCE [J].
CRAANEVANHINSBERG, WHM ;
BAX, L ;
FLINTERMAN, NHM ;
VERHOEF, J ;
JUNGINGER, HE ;
BODDE, HE .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1296-1300
[7]
Cross S. E., 2004, Current Drug Delivery, V1, P81, DOI 10.2174/1567201043480045
[8]
IONTOPHORETIC DELIVERY OF NAFARELIN ACROSS THE SKIN [J].
DELGADOCHARRO, MB ;
GUY, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 117 (02) :165-172
[9]
IONTOPHORESIS OF NAFARELIN - EFFECTS OF CURRENT-DENSITY AND CONCENTRATION ON ELECTROTRANSPORT IN-VITRO [J].
DELGADOCHARRO, MB ;
RODRIGUEZBAYON, AM ;
GUY, RH .
JOURNAL OF CONTROLLED RELEASE, 1995, 35 (01) :35-40
[10]
CHARACTERIZATION OF CONVECTIVE SOLVENT FLOW DURING IONTOPHORESIS [J].
DELGADOCHARRO, MB ;
GUY, RH .
PHARMACEUTICAL RESEARCH, 1994, 11 (07) :929-935